11440 West Bernardo Court
San Diego, CA 92127
Full Time Employees:
|Dr. Daniel Vitt||CEO, Pres & Director||N/A||N/A||1968|
|Dr. Manfred Gröppel||Co-Founder & COO||N/A||N/A||N/A|
|Dr. Andreas Mühler Ph.D.||Co-Founder and Chief Medical Officer||N/A||N/A||1963|
|Mr. Sanjay S. Patel||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Hella Kohlhof||Chief Scientific Officer||N/A||N/A||N/A|
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.
Immunic, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 7; Compensation: 9.